- Q4 2023 Oncternal Therapeutics Inc Earnings Call TranscriptMar 07, 2024$9.25 (-3.14%)Earnings
- Q3 2023 Oncternal Therapeutics Inc Earnings Call TranscriptNov 09, 2023$6 (-9.07%)Earnings
- Q2 2023 Oncternal Therapeutics Inc Earnings Call TranscriptAug 10, 2023$6.78 (-6.71%)Earnings
- Oncternal Therapeutics Inc at Jefferies Healthcare Conference TranscriptJun 07, 2023
- Q1 2023 Oncternal Therapeutics Inc Earnings Call TranscriptMay 04, 2023$6.32 (-3.60%)Earnings
- Oncternal Therapeutics Inc To Discuss Strategic Reprioritization and Capital Preservation, Extends Cash Runway into 2025 TranscriptApr 03, 2023
- Q4 2022 Oncternal Therapeutics Inc Earnings Call TranscriptMar 09, 2023$17.72 (-0.56%)Earnings
- Q3 2022 Oncternal Therapeutics Inc Earnings Call TranscriptNov 03, 2022$20 (-1.96%)Earnings
- Q2 2022 Oncternal Therapeutics Inc Earnings Call TranscriptAug 09, 2022$22.2 (-4.31%)Earnings
- Q1 2022 Oncternal Therapeutics Inc Earnings Call TranscriptMay 05, 2022$22 (+1.85%)Earnings
- Q4 2021 Oncternal Therapeutics Inc Earnings Call TranscriptMar 10, 2022$33.6 (-2.89%)Earnings
- Oncternal Therapeutics Inc Host Key Opinion Leader Webinar TranscriptJan 25, 2022
- Oncternal Therapeutics Inc to Announce Agreement with U.S. FDA on Phase 3 Registrational Study Design for Zilovertamab Call TranscriptJan 04, 2022
- Q3 2021 Oncternal Therapeutics Inc Earnings Call TranscriptNov 04, 2021$81.4 (+6.54%)Earnings
- Q2 2021 Oncternal Therapeutics Inc Earnings Call TranscriptAug 05, 2021$77.6 (+3.47%)Earnings
- Q1 2021 Oncternal Therapeutics Inc Earnings Call TranscriptMay 06, 2021$109 (-9.02%)Earnings
- Q4 2020 Oncternal Therapeutics Inc Earnings Call TranscriptMar 11, 2021$127.4 (+10.40%)Earnings
- Q2 2020 Oncternal Therapeutics Inc Earnings Call TranscriptAug 06, 2020$57.4 (-2.71%)Earnings
- Oncternal Therapeutics Inc Key Opinion Leader (KOL) Webinar on Cirmtuzumab for Treating Patients with Mantle Cell TranscriptJul 29, 2020
- Q1 2020 Oncternal Therapeutics Inc Earnings Call TranscriptMay 07, 2020$50 (-5.87%)Earnings
- Q4 2019 Oncternal Therapeutics Inc Earnings Call TranscriptMar 16, 2020$66.6 (+3.26%)Earnings
- Q3 2019 Oncternal Therapeutics Inc Earnings Call TranscriptNov 07, 2019$115.6 (-3.99%)Earnings
- Q2 2019 Oncternal Therapeutics Inc Earnings Call TranscriptAug 08, 2019$88.6 (+3.75%)Earnings
- GTx, Inc and Oncternal Therapeutics Enter into Definitive Merger Agreement to Create Nasdaq-Listed Clinical-Stage Company Call TranscriptMar 07, 2019
Q1 2021 Oncternal Therapeutics Inc Earnings Call Transcript
Good day, ladies and gentlemen, and welcome to your Oncternal Therapeutics, Inc. First Quarter 2021 Financial Results Call. (Operator Instructions)
At this time, it is my pleasure to turn the floor over to your host, Richard Vincent. Sir, the floor is yours.
Thank you, Melinda. Good afternoon, everyone, and thank you for joining us today. Joining me on the call this afternoon are our President and CEO, Dr. James Breitmeyer; and our Acting CMO, Dr. Edwina Baskin-Bey. We welcome all of you. Today's call includes a business update and discussion of our 2021 first quarter financial results, which will be followed by Q&A. Today's press release and a replay of today's earnings call will be available on the Investor Relations section of Oncternal's website for at least the next 30 days. We also filed our 10-Q for the first quarter 2021 earlier today.
Please note that certain information discussed on the call today is covered under the safe harbor provisions of the
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)